Valvosoft®
A Non-Invasive Ultrasound Therapy (NIUT) device for the treatment calcific, symptomatic, severe aortic stenosis.
Soften the aortic valve without replacing it through a surgical procedure
To treat calcific Aortic Stenosis (AS), Cardiawave has developed a Non-Invasive Ultrasound Therapy (NIUT). NIUT consists in softening the aortic valve, not replacing it. No surgery is required.
A unique approach could represent both an alternative for patients not recommended for SAVR/TAVR (Surgical/Transcatheter Aortic Valve Replacement) or refusing such intervention, and a complementary approach to current procedures to prepare overly calcified aortic valves before the deployment of a TAVR.
EU & US Regulatory Status Notice
Valvosoft® is a CE-marked medical device in the European Union when intended for the treatment of patients with severe symptomatic calcific Aortic Stenosis (AS) by non-invasive ultrasound therapy (NIUT). In the United States of America, Valvosoft® is not yet approved by the FDA and is not commercially available.
An underlying disruptive technology
Valvosoft®, delivers focused high-intensity ultrasound with precision to perform a remote and reparative effect on the aortic valve leaflets. The energy is mechanical (cavitation bubbles inducing shockwaves), non-thermal. Aortic valve leaflets tissues are softened, restoring their mobility and improving the anatomical and hemodynamical parameters following the procedure.
The disruptive and patented technology developed by Cardiawave is unique and will offer several advantages over state-of-the-art. It will allow physicians to deliver with a NIUT medical device mechanical energy on a moving target with precision, while at the same time preserving the tissue and organs through which the ultrasound passes.
Unlike any existing technology, it is possible to target and treat several anatomical zones spread over a large area without physically moving the medical device, which is placed on the patient’s chest, over the beating heart. Treatment is monitored by the user via real-time ultrasound imaging.
A pioneer’s perspective
In this 2023 interview, Professor Alain Cribier — pioneer of transcatheter aortic valve implantation (TAVI) and a former member of Cardiawave’s Scientific Advisory Board — shares his perspective on Valvosoft® and its potential in the treatment of aortic stenosis.
His insights highlight the importance of developing truly non-invasive solutions to address unmet clinical needs and improve patient care. His vision continues to inspire innovation in structural heart therapies.
Valvosoft®: Non-invasive ultrasound therapy (NIUT)
| Therapeutic Ultrasound | NIUT | Lithotripsy | HIFU* |
|---|---|---|---|
| Ability to penetrate deep in tissue | |||
| Propagation of tissue through which ultrasounds pass | |||
| Energy | Mechanical | Mechanical | Heat |
| Therapeutic effect | Tissue softening | Break-up of stone | Tissue ablation by coagulation necrosis |
* HIFU = High-Intensity Focused Ultrasound
- Focused, very high frequency and short ultrasound pulses create microscopic cavitation bubbles
- When cavitation bubbles burst, they produce shockwaves
- Shockwaves cause microcracks in valve calcium
Expected benefits and advantages
Alternative to not-recommended patients
Patients severely affected and not recommended to current medical response or refusing them can benefit from our treatment.
Non-invasive treatment
Our treatment is completely non-invasive; no surgery is required. The procedure can be done ambulatory.
Patient quality of life improved
Our solution improves the quality of life of patients.
Lower risks and complications
Valvosoft® device may decrease mortality, risks and complications.
Repeated treatment
Our treatment can be repeated.
Patients potentially treated at an earlier stage
In the future Valvosoft ® should be used as a tool to slow down the progression of the disease and be used as preventive treatment for young patients or at an earlier stage of the disease.